Summary & Overview
CPT 0739T: Malignant Prostate Tissue Ablation with Magnetic Nanoparticle Heating
CPT code 0739T denotes a novel, minimally invasive malignant prostate tissue ablation that uses a magnetic field to heat injected nanoparticles and destroy cancerous tissue. As an emerging interventional oncology technique, this code captures a targeted thermal ablation modality distinct from traditional surgical prostatectomy, radiation, or cryoablation. Nationally, the code matters because it represents an advanced device- and image-guided therapy with implications for coverage policy, facility service-line planning, and reimbursement pathways.
Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical service, typical sites of care, and payer coverage context. The publication summarizes benchmark payment considerations, coding guidance essentials tied to the CPT code, and policy trends that affect adoption for hospital outpatient departments and ambulatory surgical centers. Clinical context outlines the intended use for malignant prostate lesions and how the procedure differs from other ablative or definitive prostate cancer treatments.
The report provides benchmarking and policy update highlights, practical coding and billing notes where available, and a summary of implications for service lines evaluating the technology. Data not available in the input is clearly indicated in relevant sections.
Billing Code Overview
CPT code 0739T describes a procedure in which the provider performs malignant prostate tissue ablation by using a magnetic field to heat injected nanoparticles. The service is a form of image-guided, energy-based tumor ablation intended to destroy cancerous prostate tissue.
-
Service type: Minimally invasive malignant prostate tissue ablation using magnetic nanoparticle hyperthermia
-
Typical site of service: Hospital outpatient setting or ambulatory surgical center where interventional oncology procedures are performed
Clinical & Coding Specifications
Clinical Context
A typical patient is a 68-year-old man with biopsy-proven localized prostate cancer who is not a candidate for or declines radical prostatectomy or external beam radiation therapy. He has a focal or multifocal clinically significant tumor confined to the prostate on multiparametric MRI and targeted biopsy, and discussions of risks, benefits, and alternatives have occurred. The clinical workflow includes pre-procedure evaluation (history, PSA, prostate MRI, targeted biopsy confirmation, and anesthesia assessment), informed consent, and scheduling in an ambulatory surgical center or hospital outpatient department for image-guided focal malignant prostate tissue ablation using a magnetic field to heat systemically or locally injected magnetic nanoparticles. On the day of service the patient receives anesthesia (typically monitored anesthesia care or general anesthesia), transperineal or transrectal imaging guidance (MRI/ultrasound fusion) for nanoparticle delivery if applicable, nanoparticle injection and activation with the magnetic field device, intraprocedural monitoring for thermal effects and urinary retention, and post-procedure observation with discharge instructions. Follow-up includes PSA monitoring, repeat imaging (multiparametric MRI) and/or targeted biopsy to assess ablation efficacy and surveillance for complications such as urinary retention, hematuria, infection, erectile dysfunction, or urethral injury. Typical site of service is an ambulatory surgical center or hospital outpatient department. Service type is image-guided focal malignant prostate tissue ablation using magnetic nanoparticle hyperthermia.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work required to perform the ablation substantially exceeds typical due to complexity or time. |
23 | Unusual anesthesia | Use when general anesthesia is required for a procedure that is usually performed with local/regional or monitored anesthesia care. |
51 | Multiple procedures | Use when the ablation is billed on the same day as additional distinct procedures. |
52 | Reduced services | Use when the ablation is partially reduced or not completed as planned. |
53 | Discontinued procedure | Use when the procedure is started but terminated for patient-related or safety reasons prior to completion. |
62 | Two surgeons | Use when two surgeons with different specialties work together as primary surgeons for a portion of the procedure. |
66 | Surgical team | Use when a surgical team is required to perform the procedure due to complexity. |
78 | Unplanned return to OR following initial procedure | Use when the patient returns to the operating room for a related procedure during the global period. |
80 | Assistant surgeon | Use when an assistant surgeon participates and billing allows an assistant fee. |
81 | Minimum assistant surgeon | Use when a minimum assistant is required and documented. |
AS | Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant at surgery | Use when an advanced practice clinician serves as the surgical assistant where allowed. |
QK | Medical direction of two, three, or four concurrent anesthesia procedures | Use when the physician medically directs concurrent anesthesia services during the procedure. |
QX | CRNA service with medical direction by physician | Use when a certified registered nurse anesthetist provides anesthesia with physician medical direction. |
QY | Medical direction of one CRNA by an anesthesiologist | Use when an anesthesiologist medically directs one CRNA for the case. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 2080P0200X | Urology | Urologists commonly perform prostate-targeted ablative procedures and manage perioperative care. |
| 1744S0200X | Interventional Radiology | Interventional radiologists perform image-guided nanoparticle delivery and thermal activation. |
| 207L00000X | Radiation Oncology | Radiation oncologists may be involved in multidisciplinary selection and follow-up for focal ablative therapies. |
| 363LP0200X | Surgical Oncology | Surgical oncologists may participate in multidisciplinary planning and complex cases. |
| 2084P0800X | Medical Oncology | Medical oncologists may be involved for systemic therapy decisions in multifocal or advanced disease. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
| Data not available in the input. | Data not available in the input. | Data not available in the input. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
77021 | Magnetic resonance guidance for needle placement (eg, biopsy, aspiration, injection, localization device), imaging supervision and interpretation | Used when MRI guidance is required for nanoparticle injection or localization during the ablation procedure. |
76942 | Ultrasonic guidance for needle placement (eg, biopsy, aspiration, injection, localization device) | Used when ultrasound guidance or fusion ultrasound-MRI guidance is used for transperineal or transrectal nanoparticle delivery. |
99232 | Subsequent hospital care, per day, for evaluation and management of established patient | Used for post-procedure inpatient daily evaluation if the patient requires hospital observation beyond routine ambulatory recovery. |
99152 | Moderate sedation services provided by the same physician performing the diagnostic or therapeutic service (procedural sedation) | Used if moderate sedation is provided by the proceduralist rather than anesthesia personnel. |
90901 | Therapeutic apheresis, not otherwise specified | Data not applicable — Data not available in the input. |